SynDermix attends BIO-Europe 2018, Europe’s largest biotechnology networking and partnering annual conference.
ZURICH, SWITZERLAND — 5 November 2018
The management of SynDermix announced today that the Company will be attending BIO-Europe 2018, Europe’s largest biotechnology networking and partnering annual conference. Organised by the EBD Group in alliance with the Biotechnology Industry Organization (BIO), the three-day event kicks off in Copenhagen today, where SynDermix will be represented by the Company’s Associate Director of Strategic Development and Implementation, Ms Johanna Wolf. “We are looking forward to connecting SynDermix with industry professionals from around the world and to talk with them about our projects,” said Mr Dieter Hemmer, SynDermix’s Delegate of the Board and Chief Executive Officer. “We expect that BIO-Europe will be a perfect forum to discuss and explore new business development opportunities in relation to our therapeutic recombinant plant lectins pipeline, as well as our proprietary nitric oxide technology platform. Our schedule for this event is already looking quite busy.” The lectins pipeline of SynDermix currently targets cancer therapy-induced mucosal disorders where there is an unmet medical need, while its nitric oxide pipeline focuses on topical treatments for dermatological disorders. The Company further drives a vibration therapies pipeline of electronic medical devices which enable localised, low-frequency vibration to penetrate the tissues and to induce accelerated airway mucociliary transport time, pain relief and soft tissue regeneration.
About SynDermix AG
SynDermix AG is a Swiss developer of innovative health technologies funded by private investors. The Company focuses on the development of effective and safe treatments that meaningfully respect patient convenience and address important unmet medical needs.
SynDermix has built a diversified portfolio of innovative assets which correspond to three distinct proprietary technology platforms: smart medical devices based on digital acoustic modulation; drugs and medical devices based on a topical nitric oxide-releasing formulation; and drug candidates based on a recombinant plant lectin. Its business model is to a large extent virtual, driven by a strategy of in-licensing, outsourcing and out-licensing; the Company enters into strategic partnerships with third parties for the acquisition, development and commercialisation of a robust portfolio of assets with high innovation value and commercial potential. For more information please visit: www.syndermix.ch
Contact:
SynDermix Management AG
Julian Heinrich
Administration
+41 44 366 40 16